BWX Technologies (BWXT) Q4 2025 earnings review
Record Backlog and Surging Commercial Sales Mask Cash Flow Hiccups
BWXT capped off a transformative 2025 by ending the year with a massive $7.3 billion backlog (+50% YoY). The commercial nuclear renaissance is no longer just a narrative; it is printing hard numbers, with Commercial Operations revenue nearly doubling in Q4. However, underneath the surface, Q4 operating cash flow plummeted 54% due to working capital timing, and Government Operations revenue slightly contracted. Management initiated a very confident 2026 guidance, projecting ~17% revenue growth, validating that secular tailwinds in clean energy and national security are translating directly into long-term financial results.
🐂 Bull Case
The company's backlog grew from $4.8 billion in 24Q4 to $7.3 billion in 25Q4, driven by multi-year naval propulsion, special materials, and commercial nuclear power awards. This provides exceptional revenue visibility into the next decade.
The acquisitions of A.O.T. and Kinectrics are outperforming expectations, transforming the Commercial Operations segment from a steady grower into a high-growth engine.
🐻 Bear Case
Q4 Free Cash Flow collapsed 75% YoY to $56.8 million. While management attributes this to the timing of advanced billings and working capital, the severe disconnect from Net Income growth is a red flag for earnings quality in the quarter.
Government Operations reversed into a 1% revenue decline in Q4, with operating income dropping 8%. Lower naval component material procurement and shifting program mix temporarily suppressed the company's historical core.
⚖️ Verdict: 🟢
Bullish. The 50% backlog expansion and incredibly strong 2026 guidance overshadow the Q4 cash flow timing issues. BWXT has effectively cornered a lucrative duopoly in defense nuclear and is rapidly scaling as a merchant supplier in the commercial nuclear space.
Key Themes
Commercial Operations Surge
Accelerating. The Commercial Operations segment was the absolute standout, surging 95% YoY in Q4 to $297.7 million. This was driven by a powerful combination of organic demand for field services, fuel, components, medical sales, and the accretive impact of the Kinectrics acquisition. This segment is no longer a secondary player; it is now driving the consolidated growth profile.
Strategic Backlog Explosion
Accelerating. Total backlog expanded by $2.4 billion over the last 12 months, ending at $7.3 billion. Government Operations backlog hit $5.54 billion, providing deep multi-year visibility, heavily insulated from macroeconomic shocks.
Nuclear Renaissance Tailwind
Stable. The macro backdrop for BWXT remains exceptionally strong, operating at the intersection of national security and commercial nuclear power. Bipartisan support for domestic uranium enrichment, continued naval propulsion cadence, and utility life-extension projects are driving structural demand that outpaces current supply chain capacity.
Medical Isotope Scaling
Stable. BWXT Medical continues to grow, fueled by PET and diagnostic products. Previous quarter commentary indicated Ytterbium-176 capacity was increased by 500% to over 500 grams annually. While the Tc-99 launch timeline has faced delays, the underlying organic growth of the medical portfolio remains robust.
Q4 Free Cash Flow Plunge
Reversing. A glaring contradiction to the positive revenue and earnings narrative: Q4 Operating Cash Flow plummeted 54% YoY to $127.0M, dragging Free Cash Flow down 75% to $56.8M. Management attributes this to the 'timing of cash flows throughout the year.' A look at the quarterly data shows 2024 cash flow was massively backloaded into Q4, while 2025 cash generation was front-loaded in Q2 and Q3. Still, the sudden Q4 drop warrants monitoring.
Government Operations Hits a Speed Bump
Reversing. After posting double-digit growth in H1 2025, Government Operations revenue fell 1% in Q4 to $589.1 million. Operating income suffered an even sharper 8% decline. The company cited lower naval nuclear component material procurement and slightly lower microreactor revenue. With new special materials contracts structurally carrying lower margins in their early phases, this segment's profitability may stagnate despite massive backlog.
M&A Friction Squeezing GAAP Margins
Decelerating. While Commercial Operations revenue surged 95% in Q4, GAAP operating income grew only 37%. The culprit: $15.2 million in acquisition-related costs and $3.1 million in acquisition-related amortization in Q4 alone. While Non-GAAP margins held up better, the cash cost of integrating Kinectrics and A.O.T. is a tangible drag on the bottom line.
Other KPIs
Accelerating. Up 20% YoY. BWXT is in a heavy investment cycle, expanding the Cambridge manufacturing plant to support commercial nuclear demand and building out facilities for new government programs. This high capital intensity is currently capping Free Cash Flow conversion.
Deteriorating. Increased from $(44.1) million in 2024. The increase was primarily driven by heavy acquisition due diligence, integration, and restructuring expenses associated with the A.O.T. and Kinectrics deals.
Guidance
Accelerating. The guidance implies approximately 17% YoY growth, maintaining the aggressive double-digit expansion pace set in 2025 (+18%). This signals high confidence that backlog will smoothly convert into revenue.
Decelerating slightly. The midpoint ($4.625) implies 15.3% YoY growth, a slight step down from the 20% growth achieved in 2025, but still an exceptionally strong target that factors in lower margin mix from new government contracts and higher depreciation from the current CapEx cycle.
Decelerating. The midpoint ($652.5M) implies a 13.6% YoY growth rate, lagging the ~17% revenue growth. This confirms management's prior commentary that large new special materials contracts will carry below-average margins in their initial phases.
Decelerating. The midpoint implies just 5.8% YoY growth, drastically lagging EBITDA and Net Income growth. Heavy working capital requirements for new contracts and sustained high capital expenditures (guided historically at 5.5-6% of sales) are absorbing the cash generated from operations.
Key Questions
Q4 Cash Flow Disconnect
Operating cash flow fell 54% in Q4 despite record net income, with 'timing' cited as the primary reason. Can you provide specific details on the working capital buildup and when we should expect these advanced billings to normalize into cash?
Government Segment Margin Trough
Government Operations revenue contracted slightly in Q4. With new, large Special Materials contracts (like DUECE and HPDU) ramping up at lower initial margins, have we reached the trough for this segment's operating margin, or should we expect further compression in 2026?
Commercial Margin Normalization
Commercial Operations grew an impressive 95% in Q4, but GAAP operating margins were compressed by significant acquisition-related costs. What is the timeline for Kinectrics to be fully integrated, and what is the normalized run-rate margin for this segment exiting 2026?